Studies have observed that statins attenuate the inflammatory effect of IL-6 and IL-17 and modulate the anti-inflammatory effect of ACE2 in both ILD-PF and infection-induced pulmonary fibrosis [13,14], leading to reduced risks of CAD and stroke (S1 Appendix) [6,14–16]. Here, IL6 is linked to pulmonary fibrosis.